Cytokinetics
Trade Cytokinetics 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About CYTK
Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility.
CYTK Key Statistics
Stock Snapshot
With a market cap of 10.04B, Cytokinetics(CYTK) trades at $72.21. The stock has a price-to-earnings ratio of -9.96.
During the trading session on 2026-09-03, Cytokinetics(CYTK) shares reached a daily high of $73.55 and a low of $71.58. At a current price of $72.21, the stock is +0.9% higher than the low and still -1.8% under the high.
Trading volume for Cytokinetics(CYTK) stock has reached 149.24K, versus its average volume of 1.89M.
Over the past 52 weeks, Cytokinetics(CYTK) stock has traded between a high of $88.31 and a low of $47.22.
Over the past 52 weeks, Cytokinetics(CYTK) stock has traded between a high of $88.31 and a low of $47.22.
CYTK News
...
New insider activity at Cytokinetics ( (CYTK) ) has taken place on September 1, 2026. Director Lynne Parshall recently executed a notable insider transaction in...
Cytokinetics Incorporated (NASDAQ:CYTK) on Friday shared primary results from the ACACIA-HCM Phase 3 clinical trial of aficamten in patients with symptomatic no...
Analyst ratings
91%
of 22 ratingsMore CYTK News
Advertisement Why Cytokinetics Is Back In Focus After New HCM Trial Data Cytokinetics (CYTK) is back on many investors’ radar after fresh Phase 3 data on afic...
The latest announcement is out from Cytokinetics ( (CYTK) ). On August 28, 2026, Cytokinetics reported positive primary results from its pivotal Phase 3 ACACIA...
Cytokinetics (CYTK) announced the primary results from ACACIA-HCM, the Phase 3 clinical trial of aficamten in patients with symptomatic non-obstructive hypertro...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.